Shares of Agenus Inc. (NASDAQ:AGEN – Get Free Report) have been given an average rating of “Hold” by the five ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $26.33.
Several research firms recently issued reports on AGEN. Chardan Capital started coverage on Agenus in a research note on Friday, September 18th. They set a “buy” rating and a $40.00 target price on the stock. Wall Street Zen downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Weiss Ratings lowered shares of Agenus from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 21st. B. Riley Financial reissued a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a research report on Thursday, July 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th.
Get Our Latest Stock Report on AGEN
Institutional Investors Weigh In On Agenus
Agenus Stock Performance
Agenus stock opened at $8.50 on Friday. The company has a market capitalization of $383.86 million, a PE ratio of 3.29 and a beta of 1.38. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $8.85. The firm has a 50 day moving average price of $7.33 and a 200 day moving average price of $4.91.
Agenus (NASDAQ:AGEN – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.The firm had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. As a group, equities research analysts forecast that Agenus will post -0.28 earnings per share for the current year.
About Agenus
Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers.
The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies.
Recommended Stories
- Five stocks we like better than Agenus
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
